Allogeneic blood stem cell transplantation in advanced hematologic cancers

Bone Marrow Transplantation

Volumn 19, Issue 5, 1997, Pages 455-460

  Przepiorka, D ^a,b   Anderlini, P ^a   Ippoliti, C ^a   Khouri, I ^a   Fietz, T ^a   Thall, P ^a   Mehra, R ^a   Giralt, S ^a   Gajewski, J ^a   Deisseroth, A B ^a   Cleary, K ^a   Champlin, R ^a   Van Besien, K ^a   Andersson, B ^a   Korbling M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic blood stem cell transplant; Leukemia; Treatment related mortality

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ARTICLE; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYSTITIS; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

EID: 0031040240     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700692     Document Type: Article

References (15)

1. Körbling M, Przepiorka D, Huh YO et al. Successful allogeneic blood stem cell transplantation for refractory acute myelogenous leukemia: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
2. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
3. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
4. Przepiorka D, Ippoliti C, Giralt S et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 1994; 14: 449-453.
5. Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity, laboratory effects and analysis of charges for filgrastim mobilization and blood stem cell apheresis from normal donors. Transfusion 1996; 36: 590-595.
6. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
7. Yam P, Petz LD, Ali S et al. Development of a single probe for documentation of chimerism following bone marrow transplantation. Am J Hum Genet 1987; 41: 867-881.
8. Snover DC. Biopsy interpretation in bone marrow transplantation. In: Rosen PP, Fechner RE (eds). Pathology Annual, Part 2. Appleton & Lange: Hartford, CT, 1989, pp 63-101.
9. Przepiorka D, Weisdorf D, Martin P et al. Report of the 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
10. Körbling M, Fliedner TM, Holle R et al. Autologous blood stem cell (ABSCT) vs purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991; 7: 343-349.
11. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
12. Gordon B, Haire W, Ruby E et al. Factors predicting morbidity following hematopoietic stem cell transplantation (HSCT). Blood 1993; 82 (Suppl 1): 165a (Abstr.).
13. Chang E, Parker J, Watkins K et al. Megakaryocytic progenitors in peripheral blood (PB) and bone marrow (BM) harvested for autologous transplantation as determined by CD41a (GPIIb/IIIa) and CD14. Blood 1995; 86 (Suppl 1): 981a (Abstr.).
14. Owens AH, Santos GW. The induction of gratt-versus-host disease in mice treated with cyclophosphamide. J Exp Med 1968; 128: 277-291.
15. dim) and lymphoid subsets, and possible predictors of engraftment. Blood 1995; 86: 2842-2848.